ArticleMDM policy & practice
Development and Acceptability Testing of a Patient Decision Aid on Levodopa Intestinal Gel for Parkinson Disease.
Article in MDM policy & practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinicians' views on a patient decision aid for deep brain stimulation in Parkinson's disease.Frontiers in human neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is a neurodegenerative disease characterized by motor and nonmotor symptoms that worsen over time. In some cases, an advanced treatment may be needed. The use of levodopa-carbidopa intestinal gel (LCIG) is one of these options. However, deciding whether to receive it can be difficult. A patient decision aid (PDA), a tool designed to inform about treatment options, can help and promote patients' participation in decision making. Objectives: This study was conducted to develop a PDA on LCIG and assess its acceptability. Methods: The International Patient Decision Aid Standards framework was used to develop the PDA. An advisory committee ( Results: Sample characteristics were a mean age of 64.4 y ( Highlights: Deciding whether to opt for an advanced Parkinson's disease treatment such as levodopa-carbidopa intestinal gel can be challenging for many patients.A patient decision aid on levodopa-carbidopa intestinal gel for Parkinson's disease persons, caregivers, and health care professionals was developed to support a decision-making process.This article summarizes the steps used for its development and its acceptability testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.